PCSK9 and metabolic disease: Taken together, these data indicated that YY1 induced by ox-LDL treatment activated PCSK9 in RAW264.7 cells, resulting in the degradation of LDLR at protein level, which ultimately led to intracellular inflammatory response as well as lipid and cholesterol metabolism disorders.